The US company Immusoft has dosed the first subject with its investigational engineered B cell therapy, ISP-001, in a human Phase I clinical trial of mucopolysaccharidosis type I (MPS I).

The start-up has also been certified as a medical device manufacturer in the EU. Its x-c-bleeding product uses AI-based software to predict the risk of post-operative bleeding in patients in intensive care units.

The start-up has dosed the first participant in a Phase I study with its lead candidate HRX-0215. The small molecule holds strong potential to restore the liver’s natural capacity to regenerate itself, both in acute and chronic liver disease.